The Norwegian Research Council has announced that it received 737 research proposals from ME/CFS patients and their families in response to a call for ideas in April. Patients and others were invited to send in their ideas by May 3, using a short online form. In the call for proposals in April, Mr Hallén had
A recent Australian study, Progressive Brain Changes in Patients With Chronic Fatigue Syndrome: A Longitudinal MRI Study finds that CFS patients meeting both Fukuda and CCC have decreased grey and white matter volumes in the areas of the brain we use for language processing. Interestingly, patients had increased grey matter volume in the supplementary motor
________ Note: This article has been updated to provide context about the long-running controversy over the CMRC’s inclusion of of not only biomedical scientists but of researchers who take a biopsychosocial approach to ME/CFS. Some of this context was supplied in our earlier piece announcing the livestreaming of the AGM but we accept that many
A pdf of this article is now available here. On 21 April Dr Avindra Nath gave a Solve ME/CFS Initiative webinar hosted by Dr Zaher Nahle. The phrase that stood out in Dr Avindra Nath’s description of the NIH ME/CFS study was ‘world-class’. He emphasized the innovative technology the NIH has at its disposal, and
Dr. Zaher Nahle from the Solve ME/CFS Initiative recently interviewed Dr. Avi Nath, who is leading the intramural study on ME/CFS at the NIH. The intramural study on ME/CFS at the NIH has raised some concerns in the ME/CFS community: the appointment of Dr. Walitt, who has made statements implying that he views ME/CFS as
At the NIH tele-briefing on Tuesday, March 8th, Dr Walter Koroshetz, Director of NINDS set out the NIH’s strategy for tackling ME/CFS. He said it won’t be an easy task ‘else it would have been solved long ago’, and it wasn’t clear where the solution will come from. The NIH’s focus will be on attracting
Australian senator asks medical research council about ‘remarkably small amount of funding since 2000’ and are they funding GET or CBT .
Patients in the UK’s north east will benefit from muscle abnormality research put into action via hospitals.
Hemispherx Biopharma research shows that CFS patients who can perform more than 9 minutes on a treadmill are more likely to benefit from Ampligen.
